Amneal Pharmaceuticals Dirección

Dirección controles de criterios 4/4

El CEO de Amneal Pharmaceuticals es Chirag Patel , nombrado en Jan 2005, tiene una permanencia de 19.83 años. compensación anual total es $2.37M, compuesta por 31.6% salario y 68.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 7.04% de las acciones de la empresa, por valor de $196.23M. La antigüedad media del equipo directivo y de la junta directiva es de 5.3 años y 6.5 años, respectivamente.

Información clave

Chirag Patel

Chief Executive Officer (CEO)

US$2.4m

Compensación total

Porcentaje del salario del CEO	31.6%
Permanencia del CEO	19.8yrs
Participación del CEO	7.0%
Permanencia media de la dirección	5.3yrs
Promedio de permanencia en la Junta Directiva	6.5yrs

Actualizaciones recientes de la dirección

Recent updates

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Nov 10

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Jul 10

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Apr 15

Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Mar 19

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Dec 28

These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Apr 18

Amneal Pharmaceuticals: Risk Still Persists

Jan 23

Amneal Pharma reaffirms 2022 guidance

Jan 10

Amneal joins hands with Orion to commercialize generic products in Europe and more countries

Jan 04

Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load

Dec 20

Amneal Pharmaceuticals large shareholder TPG cuts stake

Dec 14

FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203

Nov 11

Amneal Pharmaceuticals Q3 2022 Earnings Preview

Nov 03

Amneal Pharmaceuticals: A Small 'Thumbs Up'

Oct 28

Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet

Sep 01

Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment

Aug 31

Amneal Pharmaceuticals Q2 2022 Earnings Preview

Aug 04

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chirag Patel en comparación con los beneficios de Amneal Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$184m
Jun 30 2024	n/a	n/a	-US$175m
Mar 31 2024	n/a	n/a	-US$169m
Dec 31 2023	US$2m	US$750k	-US$84m
Sep 30 2023	n/a	n/a	US$10m
Jun 30 2023	n/a	n/a	-US$2m
Mar 31 2023	n/a	n/a	-US$135m
Dec 31 2022	US$5m	US$750k	-US$130m
Sep 30 2022	n/a	n/a	-US$132m
Jun 30 2022	n/a	n/a	-US$134m
Mar 31 2022	n/a	n/a	US$2m
Dec 31 2021	US$5m	US$724k	US$11m
Sep 30 2021	n/a	n/a	US$14m
Jun 30 2021	n/a	n/a	US$9m
Mar 31 2021	n/a	n/a	-US$17m
Dec 31 2020	US$2m	US$1	US$91m
Sep 30 2020	n/a	n/a	US$62m
Jun 30 2020	n/a	n/a	-US$194m
Mar 31 2020	n/a	n/a	-US$199m
Dec 31 2019	US$446k	US$44k	-US$362m
Sep 30 2019	n/a	n/a	-US$339m
Jun 30 2019	n/a	n/a	-US$67m
Mar 31 2019	n/a	n/a	-US$69m
Dec 31 2018	US$325k	n/a	-US$21m

Compensación vs. Mercado: La compensación total de Chirag($USD2.37M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD6.55M).

Compensación vs. Ingresos: La compensación de Chirag ha sido consistente con los resultados de la empresa en el último año.

CEO

Chirag Patel (57 yo)

19.8yrs

Permanencia

US$2,370,385

Compensación

Mr. Chirag K. Patel has been Co-Chief Executive Officer, President and Director of Amneal Pharmaceuticals, Inc. since August 3, 2019. Mr. Patel Co-founded Amneal Pharmaceuticals LLC in 2005 and serves as D...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Chirag Patel	Co-Founder	19.8yrs	US$2.37m	7.04% $ 196.2m
Chintu Patel	Co-Founder	22.8yrs	US$2.37m	8.16% $ 227.6m
Anastasios Konidaris	Executive VP & CFO	4.7yrs	US$1.89m	0.17% $ 4.8m
Jason Daly	Senior VP	2.8yrs	US$1.35m	0.019% $ 516.4k
Nikita Shah	Executive VP & Chief Human Resources Officer	10.8yrs	US$1.53m	0.094% $ 2.6m
Andrew Boyer	Executive VP & Chief Commercial Officer of Generics	6.8yrs	US$1.94m	0.083% $ 2.3m
Anthony DiMeo	Head of Investor Relations	no data	sin datos	sin datos
Gregory Sgammato	Senior Vice President of Corporate Development	1.8yrs	sin datos	sin datos
Pranav Mehta	Senior VP of Strategic Sourcing & Supply Management	1.8yrs	sin datos	sin datos
Sanjay Jain	Chief Quality Officer	5.8yrs	sin datos	sin datos
Srinivas Kone	Senior VP & Chief Scientific Officer of Generics	4.8yrs	sin datos	sin datos
Stanley Fisher	Vice President & Head of Medical Affairs	no data	sin datos	sin datos

5.3yrs

Permanencia media

54.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AMRX es experimentado (5.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Chirag Patel	Co-Founder	19.8yrs	US$2.37m	7.04% $ 196.2m
Chintu Patel	Co-Founder	22.8yrs	US$2.37m	8.16% $ 227.6m
Paul Meister	Independent Chairman of the Board	5.3yrs	US$299.08k	0.24% $ 6.6m
J. Buchi	Independent Director	6.5yrs	US$302.20k	0.085% $ 2.4m
Ted Nark	Independent Director	6.5yrs	US$244.70k	0.097% $ 2.7m
Shlomo Yanai	Independent Director	4.9yrs	US$254.70k	0.079% $ 2.2m
Jeffrey George	Independent Director	4.9yrs	US$277.20k	0.087% $ 2.4m
Gautam Patel	Director	6.5yrs	US$217.20k	0.66% $ 18.5m
Deborah Autor	Independent Director	2.3yrs	US$267.04k	0.030% $ 841.3k
Emily Alva	Independent Director	6.5yrs	US$217.20k	0.081% $ 2.3m
John Kiely	Independent Director	4.9yrs	US$284.70k	0.083% $ 2.3m

6.5yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de AMRX se considera experimentada (6.5 años de antigüedad promedio).

Amneal Pharmaceuticals Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Insider recently sold US$775k worth of stock

Insider notifies of intention to sell stock

Independent Director recently sold US$256k worth of stock

Independent Director notifies of intention to sell stock

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Insider exercised options and sold US$332k worth of stock

Recent updates

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023)

Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024

New major risk - Shareholder dilution

Amneal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Insider recently sold US$775k worth of stock

Insider notifies of intention to sell stock

Second quarter 2024 earnings released: EPS: US$0.019 (vs US$0.078 in 2Q 2023)

Amneal Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year 2024

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

Amneal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 09, 2024

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Amneal Pharmaceuticals, Inc. Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant

Amneal Pharmaceuticals, Inc. Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies

Independent Director recently sold US$256k worth of stock

Independent Director notifies of intention to sell stock

Price target increased by 13% to US$8.25

New major risk - Negative shareholders equity

First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)

Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA)

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Price target increased by 7.3% to US$7.31

Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Insider exercised options and sold US$332k worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 17%

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024

Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company

Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

New major risk - Financial position

Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt

Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Calcium Gluconate Injection

Amneal Pharmaceuticals, Inc. Publishes Phase 3 Study Results Comparing Ipx203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease

Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

Price target increased by 50% to US$5.25

Amneal Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Amneal Pharmaceuticals, Inc. Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

Amneal Pharmaceuticals Could Have An Upbeat Q2

Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Amneal Launches Authorized Generic for Xyrem® (Sodium Oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

Amneal Receives 505(B)(2) Nda Approval from FDA for PEMRYDI RTU, A Ready-To-Use Oncology Injectable

Consensus EPS estimates fall by 25%

Amneal Pharmaceuticals, Inc. Launches Third Biosimilar with FYLNETRA™? (pegfilgrastim-pbbk) in the United States

Price target decreased by 18% to US$3.50

Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Price target decreased by 18% to US$4.20

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Amneal Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Amneal Pharmaceuticals: Risk Still Persists

Amneal Pharma reaffirms 2022 guidance

Amneal joins hands with Orion to commercialize generic products in Europe and more countries

Insufficient new directors

Amneal Pharmaceuticals, Inc. Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load

Amneal Pharmaceuticals large shareholder TPG cuts stake